期刊文献+

氯吡格雷药物相互作用研究进展 被引量:15

原文传递
导出
摘要 目的:探讨氯吡格雷药物相互作用的研究进展。方法:检索近年来国内外相关文献,进行归纳和总结。结果:本文系统地对抗血小板药物-氯吡格雷与他汀类、质子泵抑制剂类(PPI)、钙拮抗剂及其他药物间的联合相互作用进行了阐述,重点阐述了与他汀类、质子泵抑制剂类的相互作用,并简要介绍了CYP2C19基因的多态性与氯吡格雷抵抗的相关性。结论:根据目前的临床数据,他汀类与PPI类对氯吡格雷的抗血小板作用的影响结论不一,但大型临床统计试验倾向于他汀类不影响氯吡格雷的抗血小板疗效,泮托拉唑、雷贝拉唑对氯吡格雷的抗血小板疗效的影响较小,而奥美拉唑、埃索美拉唑已有明确的证据证明联合用药将会降低氯吡格雷的抗血小板作用。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第13期1123-1127,共5页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献31

  • 1Clarke TA,Waskell LA. The Metabolism of clopidogrel is cata- lyzed by human cytochrome P450 3A and is inhibited by atorv- astatin [J]. Drug Metab Dispos,2003,31 ( 1 ) : 53-59.
  • 2Herbert J M, Frehel D, Valle E, et al. Biochemical and pharma- cological properties of clopidogrel: a new ADP receptor antago- nist[J]. Eur Heart J, 1999(suppA) :A21-A40.
  • 3Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of dopidogrel to inhibit platelet aggregation: a new drug- dg interaction[J]. Circulation, 203, 107( 1 ) : 32-37.
  • 4Neubaner H, Gunesdogan B, Hanefeld C, et al. Lipophilic statin interfere with the inhibitory effects of elopidogrel on plateletfunction- a flow cytometry study [J]. Eur Heart J, 21)03, 24(19) : 1744-1749.
  • 5Adnan K, Nicolas VB, Alexander J, et al. Loading with 600rag clopidogrel in patients with coronary artery disease with and- without chronic clopidogrel therapy [J]. Circulation, 2004,110 (14):1916-1919.
  • 6赵水平,张大庆.阿托伐他汀与氯吡格雷相互作用的争议及评价[J].中国医药导刊,2004,6(1):56-58. 被引量:7
  • 7Serebruany VL, Midei MG, Malinin AI, etal. Absence of in- teraction between atorvastatin or ot her statins and clopidogrel: results from the interaction study [J]. Arch Intern Med, 2004, 164(18) :2051-2057.
  • 8Steinhubl SR, Berger PB, Mann III J T, et al. Early and sus- tained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [J]. JA- MA,2002,288 (19):2411-2421).
  • 9Weinbergen H, Gitt AK, Schiele R, et al. Comparison of clin- ical benefits of clopidogrel therapy in patients with acutecoro- nary syndromes taking atorvastatin versus other statin thera- pies [J].Am J Cardiol, 2003, 92(3) : 285 -288.
  • 10Lim MJ, Spencer FA, Gore J M, et al. GRACE Investigators. Impact of combined pharmacologic treatment with clopidogrel and a statin on ouecomes of patients with non-ST- segmentele- vation acute coronary syndromes: perspectives from a large multinational registry [J]. Eur Heart J, 2005, 26(11 ) : 1063- 1069.

二级参考文献20

  • 1Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost,2000; 84:891 - 896.
  • 2Jarvis Blair, Simpson Kerryn. Clopidogrel : A Review of its Use in the Prevention of Atherothrombosis. Drugs, 60(2) : 347-377.
  • 3Kearney AS, Crawford LF, Mehta SC, et al. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxuacid forms of the HMG - CoA reductase inhibitor, CI - 981.Pharm Res, 1993; 10:1461 - 1465.
  • 4Lea AP, McTavish D. Atorvastatin : a review of its pharmacology and therapeutic potential in the management of hyperlipidemias.Drugs, 1997;53:828 - 847.
  • 5Thummel KE,Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol, 1998; 38: 389 - 430.
  • 6Tannous M, Cheung R, Vignini A, et al. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.Thromb Haemost, 1999; 82 (5) : 1390 - 1394.
  • 7Viigimaa M, Valkman R. Lipid - lowering and anti - aggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia. Atherosclerosis 1999 May 24; 144 Suppl.1:24.
  • 8Hebert PR, Gaziano JM, Chan KS, et al.Cholesterol loweing with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA, 1997;278:1660 - 1661.
  • 9Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardic events following successful first percutaneous coronary intervention: a randomized controlled trial .IAMA, 2002;287: 3215-3 222.
  • 10Serebruany VL, Malinin AI, Kallahan KP, et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting.Atherosclerosis, 2001; 239:259 - 261.

共引文献6

同被引文献155

引证文献15

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部